LifeSci Capital analyst Oliver McCammon maintained a Buy rating on Perspective Therapeutics today and set a price target of $13.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Oliver McCammon has given his Buy rating due to a combination of factors that highlight the potential of Perspective Therapeutics’ pipeline. The company is advancing three Pb-212-based clinical-stage radiopharmaceutical therapies, including VMT-α-NET, which targets SSTR2-expressing gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Recent data from a Phase 1/2a study showed a confirmed overall response rate (ORR) of 35% among patients with nine or more months of follow-up, indicating promising efficacy.
Despite the initial ORR falling short of some expectations, McCammon sees potential for improvement in future data updates. He notes that the progression-free survival (PFS) may be a more relevant endpoint for approval, with encouraging signs that only a small number of patients have experienced disease progression. Additionally, the company’s financial position, with a cash runway of approximately 1.7 years, supports the continued development of its promising therapies.
In another report released today, JonesTrading also reiterated a Buy rating on the stock with a $18.00 price target.